Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-04-05
VinFast, Alcoa, And Regencell Are Among the Top 10 Large-Cap Gainers Last Week (March 30-April 2): Are the Others in Your Portfolio?RGC — Regencell Bioscience Holdings Ltd
NASDAQ · Pharmaceuticals · Pharmaceuticals
$28.31+70.54%Market cap11.94B
- Latest Close
- $28.31
- 30-Day Move
- +70.5%
- Market Cap
- $11.9B
- Shares Outstanding
- 494,490,000
- P/B Ratio
- 5.08
- ROE
- -52.3%
NASDAQ:RGCPharmaceuticals / PharmaceuticalsDelayed public snapshot
Regencell Bioscience Holdings Ltd
A read-only Alphactor snapshot forRegencell Bioscience Holdings Ltd. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$28.31
30-Day Move
+70.5%
Market Cap
$11.9B
Shares Outstanding
494,490,000
P/B Ratio
5.08
ROE
-52.3%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$28.31
+70.5%last 90 delayed daily bars
Market cap$11.9B
90D High
$69.00
90D Low
$16.30
Avg Volume
359,850
What stands out
RGC is up 70.5% over the last 30 trading days shown on this page.
Latest operating income is $-5M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
39.3%
Fundamentals snapshot
Latest Close
$28.31
30-Day Move
+70.5%
Market Cap
$11.9B
Shares Outstanding
494,490,000
P/B Ratio
5.08
ROE
-52.3%
ROA
-50.9%
Debt / Equity
0
Current Ratio
42.68
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-5M
Net Income
$-4M
Gross Margin
--
Net Margin
--
Current Ratio
42.68
Debt / Equity
0.00
Quality snapshot
Altman Z
32636.93
Safe
Piotroski
4
Moderate (4-6)
Cash Conversion
0.93x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2021-12-31 | $0 | $-1M | $-1M | $-767,311 |
| 2022-12-31 | $0 | $-8M | $-7M | $-6M |
| 2023-12-31 | $0 | $-6M | $-6M | $-5M |
| 2024-12-31 | $0 | $-5M | $-4M | $-4M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico', homepage_url='https://www.fool.com/', logo_url='https://s3.massive.com/public/assets/news/logos/themotleyfool.svg', name='The Motley Fool')•2026-03-07
Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right NowPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-03-04
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell and Camping World on Behalf of Stockholders and Encourages Investors to Contact the FirmPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico', homepage_url='https://www.fool.com/', logo_url='https://s3.massive.com/public/assets/news/logos/themotleyfool.svg', name='The Motley Fool')•2026-03-01
Forget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You NeedPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/benzinga.ico', homepage_url='https://www.benzinga.com/', logo_url='https://s3.massive.com/public/assets/news/logos/benzinga.svg', name='Benzinga')•2026-02-01
UnitedHealth, Trade Desk, And Unity Are Among Top 10 Large Cap Losers Last Week (Jan. 26-Jan. 30): Are the Others in Your Portfolio?After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Institutional holders snapshot
Geode Capital Management
Filed 2026-02-09
$9M
-1.6%
Citadel Advisors
Filed 2025-11-14
$636,540
--
BlackRock
Filed 2024-05-10
$1,071
--
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.